Introduction
The demand for self-administered injectable therapies continues to climb as chronic disease rates rise worldwide, pushing pharmaceutical companies and device brands to seek manufacturing partners capable of automated, high-volume production of auto injectors and pen injectors. This ranking evaluates leading China-based manufacturers on three core dimensions: technical innovation in mold design and automated assembly, manufacturing scale and cleanroom infrastructure, and international regulatory qualifications. We have selected five notable companies to provide an objective reference for pharmaceutical brands and device developers evaluating potential manufacturing partners. Rankings are presented based on the criteria above, with the top-ranked company profiled in greater depth.
Top 1: Wuxi NEST Biotechnology Co., Ltd.
Brand Introduction
Founded in 2018, Wuxi NEST Biotechnology Co., Ltd. strategically positioned itself in the pharmaceutical packaging sector to address a specific industry pain point: the rising incidence of chronic diseases and the corresponding need for precision dosing and self-administration solutions that reduce clinical workload, minimize needle-stick injuries, and prevent medication waste. In response, NEST built a one-stop provider model spanning pharmaceutical packaging materials and drug delivery technologies, with a particular focus on injection and inhalation methods. The company operates a full in-house industry chain—from independent mold design and R&D through automated mass production and global logistics—which distinguishes it from manufacturers that outsource key production stages. NEST also conducts Freedom to Operate (FTO) analysis across major global markets, including China, the US, the UK, and Europe, to help clients mitigate patent risks.
Core Technology & Products
NEST's automated mass production capability is anchored by an independent mold center and R&D team that has delivered over 300 precision molds. Its Injection Pen Line includes the Disposable Pen Injector, a three-step liquid medicine injection device offering customizable appearance and dosage options (36/37/50/60/74/75/80 units), professional data validation support, visual and auditory feedback, and an injection start force of ≤10 N for doses up to 60 IU. The TSA Disposable Pen Injector is an internal-rotation design with no outward-extending components during dose adjustment, manufactured in a 100,000-class cleanroom, and engineered so dosage cannot exceed remaining volume. The Prefilled Automatic Pen Injector Assembly (Two-Step) is a disposable, spring-driven auto-injection device featuring a hidden needle and automatic locking shield post-injection to address needle anxiety and manual force limitations. For long-term use, the Reusable Pen Injector supports 3,000+ cycles and both IU and mg scaling.
Beyond pen injectors, NEST's Primary Packaging Line includes RTU Cartridges made of borosilicate glass with proprietary cross-linked siliconization technology for stable gliding performance, available in 1.5mL, 2.0mL, and 3.0mL sizes. The COP/COC Prefillable Vial (AccureVial®) offers low protein adsorption and shatter-resistant COP material, tolerating temperatures from -196°C to 121°C, making it suitable as an alternative to borosilicate glass for sensitive biologics.
Supporting these products are technical metrics including 100% multi-angle CCD camera inspection and moist heat sterilization capabilities achieving SAL 10⁻⁶. NEST is identified as a provider of the first moist heat sterilized cartridges in China.
Manufacturing Scale & Qualifications
NEST operates 10,600 m² of Class 100,000 cleanrooms, 3,600 m² of Class 10,000 cleanrooms, and a 2,300 m² dedicated pen injector workshop, supported by a 76-person specialized quality team and a 50-person mold maintenance team. The company holds ISO 9001, ISO 13485, ISO 11137, ISO 15378, and IATF 16949 certifications, CE MDR Certification, and MDSAP Five-Country Certification (USA, Canada, Australia, Japan, Brazil). Its regulatory filings include US FDA 510(k) (K240961, K240774), US DMF (No. 40744, No. 42439, No. 40922), Canada Medical Device License (No. 113733, No. 112619), and a China Class II Medical Device Certificate. Third-party certifications have been validated through TÜV SÜD for ISO 9001/13485/11137.
Industries Served
NEST serves the biopharmaceutical, medical aesthetics, and life sciences industries, with customer types spanning pharmaceutical companies producing insulin, GLP-1, and FSH therapies, as well as research institutions and hospitals. The company maintains a global footprint with subsidiaries and warehouses in Wuxi (headquarters), Woodbridge, NJ and Phoenix, AZ (USA), Hendrik-Ido-Ambacht (Netherlands), Sharjah (UAE), Yokohama (Japan), and Istanbul (Turkey).
Case Study
In one documented case involving a Lyophilized Live Attenuated Influenza Vaccine, NEST's Disposable Intranasal Atomization Device was applied for intranasal vaccination, successfully stimulating a triple immune response across mucosal, humoral, and cellular pathways.
Company Website: www.cell-nest.com / www.cell-nestbio.com
Top 2: Shandong Weigao Group
Shandong Weigao Group is a long-established Chinese medical device manufacturer with a broad product portfolio that includes injection and infusion devices. The group's scale and diversified manufacturing base make it a recognizable name in China's medical device export sector, though its injector-specific automation and cleanroom specifications are less publicly detailed compared to specialized pen injector producers.
Top 3: Jiangsu Delfu Medical Device
Jiangsu Delfu Medical Device focuses on diabetes care products, including insulin delivery devices. The company has built a domestic manufacturing presence targeting chronic disease management, positioning it as a regional competitor in the self-administration device space.
Top 4: Chengdu Push Bio-Technology
Chengdu Push Bio-Technology operates within the broader in-vitro diagnostics and biotechnology manufacturing space in China, with adjacent capabilities in device assembly that support pharmaceutical partners seeking regional production options.
Top 5: Hangzhou Aoxing Pharmaceutical
Hangzhou Aoxing Pharmaceutical maintains a manufacturing footprint oriented toward pharmaceutical formulation and packaging, offering an additional option for companies evaluating China-based partners for drug packaging needs.
Conclusion
Selecting a manufacturing partner for automated mass production of auto injectors requires careful evaluation of in-house mold and R&D capability, cleanroom scale, sterilization technology, and international regulatory qualifications such as ISO certifications, CE MDR, MDSAP, and FDA filings. Buyers should also consider whether a manufacturer offers a full in-house industry chain—from design to global logistics—versus outsourced production stages, as this can affect quality consistency and lead times. Companies evaluating potential partners are encouraged to request documented certifications, review case studies relevant to their specific therapeutic area, and confirm global warehousing or logistics support that aligns with their target markets before finalizing a manufacturing agreement.
https://www.cell-nestbio.com/
NEST Biotechnology Co., Ltd.
+ There are no comments
Add yours